Navigating the mainstreaming of psychedelics

Abstract

Abstract This article critically addresses one of the most pressing questions of the current moment of the psychedelic wave: Is mainstreaming psychedelics a good thing? Our aim is not to provide a simple “yes” or “no” as an answer but to explore the tensions, controversies, disparities, inequalities, and risks that have risen in the last decades. We discuss the limits of psychedelic science as the paradigm leading this movement and the risks of an overemphasis on biomedicalization to the detriment of the social sciences, humanities, and traditional knowledge. We also examine policy considerations, the dangers of commodification, and the ecological burdens that the expansion of the use of psychedelics is causing. Additionally, the article reflects on the tendency to prioritize the psychotherapeutic approach to care, a topic that has been neglected in the field. The authors put forward the need for inclusion, ethics, and reciprocity to balance the inequalities that risk recreating the psychedelic movement as another expression of mainstream capitalist endeavors. Given the Food and Drug Administration's delay in approval of MDMA for PTSD and the hurdles for regulating access to psychedelics in ceremonial and therapeutic contexts, such as Colorado and Oregon, there is an urgent need to engage in an informed conversation about the future of the psychedelic movement. It is important to avoid the tendency to romanticize this landscape and to do a proper assessment of the contemporary challenges and ethical risks that we face in the future.